GRPH - Graphite Bio, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD
2.9700
+0.0500 (+1.71%)
At close: 04:00PM EDT
2.9700 0.00 (0.00%)
After hours: 04:00PM EDT
Stock chart is not supported by your current browser
Previous close2.9200
Open2.9400
Bid2.9600 x 1000
Ask2.9700 x 900
Day's range2.8700 - 2.9700
52-week range1.5900 - 4.4800
Volume106,704
Avg. volume146,382
Market cap172.566M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results

    SOUTH SAN FRANCISCO, Calif., March 20, 2023--Graphite Bio, Inc. (Nasdaq: GRPH) today reported recent business progress and fourth quarter and fiscal year 2022 financial results.

  • Business Wire

    Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring

    SOUTH SAN FRANCISCO, Calif., February 22, 2023--Graphite Bio, Inc. (Nasdaq: GRPH) today announced that it has completed a review of its business, including the status of its programs, resources and capabilities. The company has decided to discontinue further development of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease and to initiate a process to explore a range of strategic alternatives.

  • Business Wire

    Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease

    SOUTH SAN FRANCISCO, Calif., January 05, 2023--Graphite Bio, Inc. (Nasdaq: GRPH) today announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) due to a serious adverse event in the first patient dosed with nula-cel, and the company’s conclusion that the event is likely related to study treatment. As a result, the company will not meet its guidance for initial proof-of-concept data in mid-2023.

  • Business Wire

    Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting

    SOUTH SAN FRANCISCO, Calif., December 11, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today presented preclinical results supporting the use of a single-cell RNA sequencing method to assess gene correction outcomes in patients treated with nulabeglogene autogedtemcel (nula-cel), an investigational gene-edited

  • Business Wire

    Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference

    SOUTH SAN FRANCISCO, Calif., November 21, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Thursday, Dec. 1, 2022, at 11:45 a.m. ET.

  • Business Wire

    Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results

    SOUTH SAN FRANCISCO, Calif., November 09, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today reported recent business progress and third quarter 2022 financial results.

  • Business Wire

    Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition

    SOUTH SAN FRANCISCO, Calif., November 03, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that two abstracts have been accepted as part of the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held December 10-13 in New Orleans and broadcast virtually from the E

  • Business Wire

    Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention

    SOUTH SAN FRANCISCO, Calif., October 11, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of its leadership team will participate in the 50th Annual Sickle Cell Disease Association of America (SCDAA) National Convention, taking place virtually October 11-15. The Convention is being held

  • Business Wire

    Graphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., September 06, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today announced that members of the management team will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, Sept. 13, 2022, at 12:55 pm ET.

  • Business Wire

    Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results

    SOUTH SAN FRANCISCO, Calif., August 11, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today reported recent business progress and second quarter 2022 financial results.

  • Business Wire

    Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease

    SOUTH SAN FRANCISCO, Calif., August 11, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today announced that the first patient has been dosed with GPH101, now called nulabeglogene autogedtemcel (nula-cel), in the company’s Phase 1/2 CEDAR trial in people with sickle cell disease (SCD). Nula-cel is an investigational gene e